drugset / Trial / NCT07284784
A Study of Buntanetap in Participants With PD
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.
Timeline
- Start
- 2026-01-09
- Primary completion
- 2029-09
- Completion
- 2029-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | buntanetap | Small molecule | 30 mg | Oral |